We formulated and analyzed a novel nanoformulation of the anticancer drug cisplatin (Cis) with C60 fullerene (C60+Cis complex) and showed its higher toxicity toward tumor cell lines in vitro when compared to Cis alone. The highest toxicity of the complex was observed in HL-60/adr and HL-60/vinc chemotherapyresistant human leukemia cell sublines (resistant to Adriamycin and Vinculin, respectively). We discovered that the action of the C60+Cis complex is associated with overcoming the drug resistance of the tumor cell lines through observing an increased number of apoptotic cells in the Annexin V/PI assay. Moreover, in vivo assays with Lewis lung carcinoma (LLC) C57BL/6J male mice showed that the C60+Cis complex increases tumor growth inhibition, when compared to Cis or C60 fullerenes alone. Simultaneously, we conducted a molecular docking study and performed an Ames test. Molecular docking specifies the capability of a C60 fullerene to form van der Waals interactions with potential binding sites on P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP-1), and multidrug resistance protein 2 (MRP-2) molecules. The observed phenomenon revealed a possible mechanism to bypass tumor cell drug resistance by the C60+Cis complex. Additionally, the results of the Ames test show that the formation of such a complex diminishes the Cis mutagenic activity and may reduce the probability of secondary neoplasm formation. In conclusion, the C60+Cis complex effectively induced tumor cell death in vitro and inhibited tumor growth in vivo, overcoming drug resistance likely by the potential of the C60 fullerene to interact with P-gp, MRP-1, and MRP-2 molecules. Thus, the C60+Cis complex might be a potential novel chemotherapy modification.
Introduction
Chemotherapy is one of the most common cancer treatments, despite numerous side effects that significantly affect the patient [1] . An observed toxicity toward tissues and organs, namely cardiotoxicity, hepatotoxicity, nephrotoxicity, and neurotoxicity of conventional anticancer antibiotics, as well as the rapid development of tumor cell drug resistance seem to be particularly important [2, 3] .
One of the most extensively used anticancer chemotherapeutics is cisplatin (Cis-[Pt(II)(NH 3 ) 2 Cl 2 ], Cis), a water-soluble derivative of inorganic, divalent platinum [4] . The mechanisms of action of Cis include impairing DNA synthesis and, thereby, cell proliferation. However, these effects are accompanied by virtually all of the side effects mentioned above [4] . Therefore, the development of new, alternative methods of Cis delivery to tumor cells is a matter of great importance.
Modern pharmacology struggles to answer this issue, proposing novel formulations based, among others, on specific nanoscale carriers and aiming for targeted drug delivery. The main purpose of novel platinum-based anticancer formulations is to increase drug bioactivity in the organism and biocompatibility. As a solution, Huynh et al. proposed either the encapsulation of the platinum-based anticancer drugs in a polymeric matrix or their conjugation with a polymeric carrier [5] . The conjugation of drugs with a polymeric carrier not only increases the drug's bioavailability but also promotes a drug-selective transfer to the tumor growth area [6] . Moreover, the conjugation of dichloro(1,2-diaminocyclohexane)platinum(II) and nanoparticles coated with hyaluronic acid shows an increase in anticancer drug bioavailability together with effectively overcoming tumor resistance mechanisms [7] . Therefore, it can be said that novel nanocarriers should not only significantly lower the negative side effects of specific chemotherapeutic agents, but also enhance their anticancer activity [8, 9] .
In this study, we propose a C 60 fullerene (FC 60 ) as a prospective alternative platform for Cis delivery as well as other drugs. FC 60 is a carbon nanostructure reported to possess biological activity toward various cell types, both in vitro and in vivo [10] . Pristine FC 60 has been shown to be non-toxic at low concentrations [11] [12] [13] , penetrate through cell plasma membranes [14] [15] [16] , and have antioxidant activity [17, 18] . In addition, reports indicate that FC 60 alone shows anticancer activity. We described the potential of pristine FC 60 administered in a dose of 25 mg/kg to suppress the growth of transplanted Lewis lung carcinomas (LLCs) in male mice (C57BL/6J line) [19, 20] . The proposed mechanisms of FC 60 antitumor activity is based on its potential to modulate oxidative stress, inhibit angiogenesis, and stimulate an immune response [21] [22] [23] [24] [25] .
Our latest results indicate the formation of noncovalent complexes between aromatic drugs and FC 60 in a physiological solution [26, 27] . Consecutive research indicated that this phenomenon might be a key mechanism to the amplification of the antibiotic activity of the anticancer drug, doxorubicin, both in vitro and in vivo [28] [29] [30] . Panchuk et al. reported a significant increase in the doxorubicin toxicity toward various tumor lines after conjugation with FC 60 (compared to doxorubicin alone) [29] . Similarly, the therapeutic effects of such a complex was observed in male mice (C57BL/6J line) with LLC [29] . On the basis of these results, we hypothesized that other anticancer drugs may reveal similar synergy with FC 60 because of their complexation with this carrier [27, 31] . Furthermore, we recently showed that Cis forms a similar non-covalent complex with FC 60 in physiological solution, which suggests a possibility of the enhancement of analogous Cis anticancer activity after its administration with FC 60 [32] . The promising results of this research established a solid basis for further investigation of the biological significance of the observed interactions and, possibly, development of a novel chemotherapy protocol.
The main aim of this study was to assess, in detail, the potential of FC 60 to enhance Cis anticancer activity both in vitro and in vivo. We evaluated this capacity on drug-resistant human tumor cells in vitro and with an in vivo LLC mouse model. Furthermore, we analyzed a potential mechanism of the enhancement of Cis anticancer activity by using molecular docking of FC 60 to P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP-1), and multidrug resistance protein 2 (MRP-2) molecules. Additionally, we assessed whether the formation of the proposed complex affects the mutagenic activity of Cis.
Results and discussion
The two greatest problems of anticancer therapy are that conventional anticancer drugs lack specificity leading to negative side effects [1, [33] [34] [35] [36] and the development of drug resistance in tumor cells [2, 3] .
To address these problems, we prepared and analyzed a novel complex of the classic anticancer drug, Cis, with FC 60 . Previous research on FC 60 characteristics showed its biocompatibility and potential suitability to be used as a delivery platform for doxorubicin. Doxorubicin is a drug that is considered the gold chemotherapy standard [29, 30] .
Small-angle X-ray scattering data
First, we assessed the formation of the complex between Cis and FC 60 (C 60 +Cis complex) by using small-angle X-ray scattering (SAXS). The experimental SAXS curves of FC 60 and FC 60 -Cis aqueous solutions are presented in Fig. 1 . Processing of the SAXS curves using the approach developed by Glatter [37] , based on an indirect Fourier transformation, allowed us to calculate the pair distance distribution function for the investigated systems (Fig. 1) . It is important to notice that the shapes of these functions for FC 60 and the C 60 +Cis complex are different with only one maximum observed for FC 60 alone and two maxima for the complex. According to Glatter [38] , the observed phenomenon may be the consequence of the C 60 +Cis complex formation and the maxima observed for the FC 60 -Cis solution corresponded to two statistically different entities formed in the solution: FC 60 clusters and C 60 +Cis complexes (SAXS analysis of the Cis solution does not result in the scattering above 10 nm, data not shown). These results are in agreement with previously recorded outcomes using ultraviolet-visible (UV-vis) and small-angle neutron scattering (SANS) methods for a similar mixture of FC 60 and Cis [32] . Significantly, the SAXS and SANS methods are complementary and provided corresponding, qualitative results, and conclusions regarding the behavior of FC 60 and the Cis solution. Therefore, it can be concluded that the heterocomplexation of FC 60 and Cis occurs in the analyzed mixture. 60 and C 60 +Cis complex. Experimental SAXS curves (points) for FC 60 (red) and the C 60 +Cis complex (green) aqueous systems. Solid lines correspond to the model curves obtained by the indirect Fourier transformation procedure. Inset: the normalized pair distance distribution functions because of the indirect Fourier transformation procedure for scattering from the FC 60 (red) and the C 60 +Cis complex (green) aqueous systems.
Molecular docking
Molecular docking is one of the most extensively used computational tools in the simulation of biophysical systems, especially in a search for the molecular targets of new drugs [39] [40] [41] [42] . This approach is based on the exploration of the landscape of the conformational energies that the analyzed protein molecules may adopt.
In the case of P-gp, molecular docking was conducted in each of the four positions of the potential FC 60 binding (Fig. 2(a) ). On the basis of the available data [43] : position 1-the part of the protein located in the extracellular space (Extra-cell); position 2-the native binding site of the protein; position 3-transmembrane domains (Membrane interior); position 4-the part of the protein located in the intracellular space (Intra-cell). The calculated energy characteristics for the FC 60 +P-gp complex are presented in Table 1 .
FC 60 binding in positions 1, 2, and 3 is characterized by the complete filling of binding pockets and low interaction energies between FC 60 and P-gp (Table 1) . However, position 1 is characterized by significant steric clashes between the interacting structures (19.1 kJ/mol), (Fig. 2(b) ). The simulated FC 60 +MRP-1 complex is characterized by interaction energy lower than the values obtained for P-gp at any of the binding sites (-50.7 kJ/mol) and minor steric clashes (5.9 kJ/mol), comparable to those obtained for P-gp in positions 2, 3, and 4. The amino acids involved in the interactions are: Leu 692, Glu 694, Val 708, Ala 709, Tyr 710, Trp 716, Phe 728, and Arg 780 ( Fig. 2(b) ).
Finally, we performed an in silico analysis of the FC 60 interactions with MRP-2. The interaction energy calculated for the complex was the lowest (-61.5 kJ/mol) and the binding pocket of the analyzed protein was completely filled (Fig. 2(c) ). However, steric clashes between FC 60 and MRP-2 are the second highest (13.6 kJ/mol). The amino acids involved in the interactions are Leu 51, Glu 53, Thr 67, Tyr 69, Trp 75, Phe 87, and Gln 143 (Fig. 2(c) ).
The results of the molecular docking experiments indicate direct interactions between FC 60 and three of the main proteins involved in a very complex phenomenon of cancer cell drug resistance, namely P-gp [44] , MRP-1 [44] , and MRP-2 [45, 46] . All three of the analyzed proteins have the potential to directly interact with FC 60 , with the most promising results observed from MRP-2, MRP-1, and the native binding site of P-gp. However, a previous report analyzing the interactions of curcumin with MRP-1 in silico proposed that other amino acid residues are involved in the formation of the protein-binding cavity [47] . The reason for these differences may be the diverse modeling method used in this work and by Sreenivasan et al. [47] . Additionally, there is a vast difference in the structures of FC 60 and curcumin. The first is a large spherical particle, while the latter has two aromatic rings connected by a long chain of carbon atoms.
In vitro toxicity
On the basis of the promising results of the molecular docking experiments, we decided to assess the potential of the C60+Cis complex to overcome tumor cell drug resistance. We analyzed several tumor cell lines differing in their drug resistance mechanism. This included lines with knockout genes responsible for the cell cycle or apoptosis, as well as the overexpression of P-gp and MRP-1. The chosen lines belonged to three cancer types commonly treated with Cis, namely colon cancer [48, 49] , cervical cancer [50] [51] [52] , and leukemia [53] .
The results obtained after the incubation of the colon cancer cell line HCT-116 and its sublines with the C 60 +Cis complex indicate a higher cytotoxicity of the analyzed complex when compared to Cis alone. However, in the case of the HCT-116/wt cell line and its subline, HCT-116/Bax (−/−) with a Bax gene (involved in the control of the apoptosis process) knockout, where the cytotoxicity was 10%-15% higher, the increase was statistically insignificant. Nevertheless, the HCT-116/p53 (−/−) subline, with a p53 gene (involved in the regulation of the cell cycle) knockout, showed increased cytotoxic effects, as high as 20% (with concentrations of Cis and the C 60 +Cis complex equal to 5 μM), which was statistically significant (Fig. 3) .
The beneficial effects of the Cis complexation with FC 60 were even more pronounced when analyzed on the human cervical cancer cell lines. In the case of HeLa and KB-3-1 cell lines, the cytotoxic activity of the C 60 +Cis complex was 20%-25% higher than Cis alone. Interestingly, although the colchicine-resistant KBC-1 subline (overexpression of P-gp) was hypersensitive to Cis action, the C60+Cis complex still showed higher cytotoxicity (10%-15%) than Cis alone did (Fig. 3) . Nano Res. 2017, 10(2): 652-671
The biggest difference in cytotoxic activity between Cis alone and the C 60 +Cis complex was observed in the cell line most sensitive to the drug, human leukemia cell line HL-60 and its drug-resistant sublines, characterized by the expression of diverse ABC-transporter proteins (Fig. 4) . The increase of this activity was more than two-fold higher (activity of complex compared to Cis alone) and LC 50 (drug concentration in which 50% of cells are killed) for HL-60/wt was established at 0.85 μM and 0.38 μM for Cis alone and the C 60 +Cis complex, respectively. In the drug-resistant subline HL-60/adr (overexpression of MRP-1), these LC 50 values equal 17.51 and 7.67 μM, while for subline HL-60/vinc (overexpression of P-gp) equals 21.99 and 6.68 μM for Cis alone and the C 60 +Cis complex, respectively. It is important to note that a vast increase in the LC 50 values was observed for drug-resistant sublines and, consequently, the substantial impact of the Cis complexation with FC 60 on the drug cytotoxicity (Fig. 4) . At the same time, human Jurkat T-leukemia Chemotherapy resistance is a growing problem for modern medicine and is drawing increasing attention around the world [2, 3] . The resistance mechanisms analyzed in this work include Bax and p53 protein deletions, as well as the overexpression of drug resistance proteins, P-gp and MRP-1, are among the most prominent and widespread [54, 55] . Therefore, the development of novel drug delivery systems capable of increasing the anticancer activity of the drug, reducing its side effects, and sensitizing the resistant cells is a matter of great importance [7] [8] [9] . Numerous groups working on the improvement of Cis therapy have reported that several compounds have at least one of the desired properties. Sui et al. showed promising effects from the nanocarbon structure, graphene, which enhances Cis anticancer activity by increasing its uptake to the cell and its nucleus [56] . This mechanism has also been described for FC 60 [14] [15] [16] . In addition, several groups have analyzed the impact of a Cis complexation with other active substances, revealing an increase in Cis cytotoxicity against the HCT-116 cell line when complexed with shikonin [57] or dibenzo[c,h] [1,6]naphthyridin-6-ones [58] , as well as an HL-60 cell line when complexed with benzyl isothiocyanate [59] .
Numerous other groups have concentrated on overcoming the drug resistance of tumor cells. Promising results have been obtained for compounds such as curcumin [60] , cyclooxygenase inhibitors [61] , tetrandrine [62] , and melatonin [63] . However, none of these complexes has all three of the desired characteristics, in contrast to the C 60 +Cis complex analyzed in this work. Nevertheless, it has to be noted that Cis resistance is a very complex phenomenon with numerous proteins involved, including ABCtransporters such as P-gp, MRP-1 [44] , MRP-2 [64] , cellular glutathione system, and metallothioneins [64] . The role of the multidrug-resistance proteins analyzed Nano Res. 2017, 10(2): 652-671 in this work, namely P-gp and MRP-1, is confirmed in the presented results.
Assessment of the cell cycle and apoptosis
We analyzed the potential mechanism behind the increase of the Cis cytotoxic activity induced by the complexation with FC 60 by assessing the cell cycle patterns and apoptosis using fluorescent microscopy and flow cytometry. The modulation of apoptosis was assessed through observing KB-3-1 cells with hypercondensed nuclei, which are a typical hallmark for apoptosis (Fig. 5) . Neither untreated cells (Fig. 5(a) ) nor cells incubated with FC 60 (Fig. 5(d) ) undergo hypercondensation of the nuclei, therefore, it can be said that fullerene alone does not induce apoptosis in cancer cells. However, the complexation of FC 60 with Cis results in enhanced apoptosis due to the anticancer drug, which was observed as a massive increase in the percentage of shrunken cells with condensed nuclei (for 15 μM concentrations see Figs. 5(b) and 5(e) for Cis alone and the C 60 +Cis complex, respectively). The effect was even more pronounced when the concentration of the drug and complex were increased to 20 μM (Figs. 5(c) and 5(f), respectively).
To further analyze the issue and assess the hypothesis that the enhanced cytotoxic activity of the C 60 +Cis complex is the result of an increase in apoptosis, we performed an Annexin V/propidium iodide (PI) double staining of the HL-60/adr cells overexpressing MRP-1. The fluorescence of the cells was measured and presented in the form of the percentage of all counts ( Fig. 6(a) ). Notably, a higher number of apoptotic cells (Annexin V and PI positive) was observed in samples incubated with the C 60 +Cis complex than in samples incubated with Cis alone. The most pronounced effect was observed with a 15 μM dose of the analyzed substances with 10.11% and 19.16% of apoptotic cells for Cis alone and the C 60 +Cis complex, respectively ( Fig. 6(a) ). Moreover, the cell cycle analysis indicated an increase in the number of cells only in the pre-G1 phase (apoptotic), compared to Cis alone, when cells were treated with the C 60 +Cis complex. The values increased as high as two-fold for the analyzed concentrations, with data being statistically significant for concentrations of 10 and 20 μM. With a 15 μM concentration, the increase is clear as well, however, not statistically significant (Fig. 6(b) ). Importantly, both analyses provided similar, dose-dependent increases in the number of apoptotic cells induced by treatment with the C 60 +Cis complex.
Apoptosis is one of the most prominent mechanisms of Cis anticancer activity [4, 65] and the antiapoptotic potential of the drug against leukemia cell line HL-60 is well documented [53] . This phenomenon is widely used in the attempts to enhance the anticancer potential of Cis with numerous biologically active compounds, such as shikonin [54] or oridonin [66] among others. The results of the staining in this work also indicate more proapoptotic activity from the C60+Cis complex than Cis alone. Therefore, the results support the hypothesis that the C 60 +Cis complex possesses higher anticancer activity than Cis alone. Moreover, this increase may be attributed to an elevated induction of apoptosis.
Ames mutagenicity assay
To analyze a potential increase in mutagenic activity of the Cis complex with FC 60 , we used the Ames test. The experiments were conducted on bacteria (Salmonella typhimurium) and showed a significant reduction of Cis mutagenic activity after its administration together with FC 60 (Fig. 7) . However, this reduction was not dependent on the FC 60 dose, since a protective effect showed a similar level at all concentrations of FC 60 except at the lowest (10 ng/plate). This corresponds to an FC 60 :Cis molar ratio of 1:120. When this ratio was equal to 1:24, the observed protective effect did not show a statistically significant difference when compared to that observed at the highest FC 60 concentration (10 μg/plate; FC 60 :Cis molar ratio 8.3:1). The highest protective effect observed was at a concentration of 3.33 μM of FC 60 (corresponding to 0.6 μg/plate, molar ratio 1:2). This phenomenon can be attributed to an increased homoaggregation of FC 60 at high concentrations, which may reduce the number of binding sites available for Cis. Consequently, this may lead to an increased number of free, biologically active Cis particles. Nevertheless, an observed reduction of Cis mutagenic activity with lower concentrations of FC 60 shows a pattern similar to the one detected for other compounds with confirmed mutagenic activity, such as ICR-191 [67] , the heterocyclic aromatic amines [68, 69] , and anticancer drugs [70, 71] . Notably, the most effective FC 60 :Cis molar ratio in the reduction of Figure 7 Ames mutagenicity test of Cis and the FC 60 and Cis complex in Salmonella typhimurium TA102 strain. Overnight cultures of S. typhimurium TA102 were treated with 500 ng Cis or a mixture of 500 ng Cis with 0.01-10 µg FC 60 and incubated for 4 h. Subsequently, bacteria were spread on glucose minimal plates and the revertants were counted after 48 h of cultivation. Results are presented as means from three plates ± SD; *-values significantly different from cells treated with Cis alone (p < 0.05).
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Cis mutagenic activity is almost identical to the molar ratio of FC 60 :Cis used during in vitro cytotoxic studies on tumor cell lines (1:2.4). This was obtained by mixing 500 μg/mL solutions of FC 60 and Cis. We also analyzed other molar ratios of FC 60 and Cis (namely 1:0.6, 1:1.2, and 1:4.8), yet, the results have proven to be less effective when compared to the molar ratio used in the C 60 +Cis complex (Fig. S1 in the Electronic Supplementary Material (ESM)).
Antitumor action in vivo
LLC is extensively used as an experimental model in research on the efficiency of antitumor therapies [8, 29, [72] [73] [74] [75] [76] [77] . In our work, the antitumor potential of the novel C 60 +Cis complex was assessed in vivo by using this well-established model. The first parameter assessed was the tumor volume. All treatments (namely, FC 60 , Cis, and the C 60 +Cis complex) resulted in a decrease in tumor volume, when compared to that in the control (untreated) group (Fig. 8) . On day 20 of the experiment, the tumor volume in the mice in group 1 (treated with FC 60 ) and group 2 (treated with Cis alone) was 15% lower than those in the control group. The most prominent antitumor effect was observed in mice in group 3 (treated with the C 60 +Cis complex), where the decrease in tumor volume reached 75% of that of the control group (Fig. 8) .
To further assess the effectiveness of the treatment and confirm the observation that the inhibitory effects on the growth of LLC from the C 60 +Cis complex are more pronounced than either FC 60 or Cis alone, we calculated the tumor growth inhibition index (TGII) ( Table 2 ). The value of TGII in group 1 increased between day 11 and 17; however, on day 20, it rapidly decreased from 35% to 17%. An even higher decrease in the TGII value was observed in group 2 (48%-18% between day 17 and 20). Even though the reduction (52%-36%) of TGII in the last part of the experiment was observed for group 3, treated with the C 60 +Cis complex, the final value was still twice as high as the values observed for groups treated with either FC 60 or Cis alone.
LLC is characterized by a high metastasis to the lungs [78, 79] . Therefore, at the day of experiment cessation (day 22) the number of metastatic nodules on the surface of each lung lobule of every mouse, as well as their volume, were evaluated. All analyzed therapies reduced both the total volume of lung metastases and an average volume of the single metastasis; however, the average number of metastases in the mice treated with Cis alone was comparable to that treated with the control (12-13, respectively). In groups treated with either FC 60 or Cis alone, the reduction of the total metastases volume reached 73% and 57%, respectively, and the volume of the single metastasis reached 50% and 53%, respectively. We observed the most pronounced reduction in group 3, where the decrease of the total metastases volume equaled 75% and decrease in the volume of the single metastasis was 64%.
Another well-described characteristic of LLC-bearing mice is the tumor-associated cachexia [80, 81] . We evaluated the body weight of the mice after tumor removal ( Table 4 ). The body weight of the animals in the untreated control group was 28% lower than the weight of the intact animal group (mice not bearing LLC). Interestingly, the body weight of the mice treated with Cis alone (group 2) was lower than in the control by 10%, which resulted in an overall weight loss equal to 35% in healthy animals. Animals treated either with FC 60 (group 1) or the C 60 +Cis complex (group 3) had significantly lower body weight than the intact animals. However, the loss of body mass was reduced and reached 22% and 15%, respectively. The main triggering factors of cancer cachexia are systemic inflammation and disorders in lipid metabolism [82] . Therefore, one of the most extensively studied properties of FC 60 is its potential to scavenge free radicals [17, 18, 23, 24] , it could be hypothesized that the observed reduction of cancer cachexia in animals treated with FC 60 alone or the C 60 +Cis complex might be associated with this FC 60 property.
Interestingly, an increasing number of studies have reported that cytotoxic anticancer drugs, including Cis, aside of promoting apoptosis [3, 4, 83] , may act as modulators of immunological activity [84] [85] [86] [87] . Furthermore, carbon nanostructures have been reported to possess immunomodulatory activity as well [25] . Therefore, we evaluated the response of the tumor bearing mouse immune system with the proposed treatment by calculating the thymus and spleen weight indices. All proposed treatments resulted in a significant decrease in the splenic index when compared to the control. However, the observed values were still 28%-44% higher than the one calculated for the intact animals. Interestingly, the thymic index value calculated for untreated animals was comparable to the healthy animals while every treatment resulted in a decrease of the thymus weight (Table 5) . Furthermore, the growth of LLC is associated with moderate splenomegaly, a manifestation of hematological paraneoplastic syndrome [88] . The weight of the spleen of mice undergoing any treatment (including the C 60 +Cis complex) was significantly lower than in the control (untreated) group of LLC bearing mice. This phenomenon was also observed in the splenic indices, however, the value calculated for mice treated with Cis alone (group 2) was relatively higher than the values obtained for groups treated with FC 60 and the C 60 +Cis complex. We can hypothesize that the observed relative decrease in the thymus weight may be a result of either an increase of thymocyte apoptosis, decrease in thymocyte proliferation, or an increase in the translocation of thymocytes from the organ to the periphery. Numerous reports have indicated an internalization of FC 60 by murine dendritic cells [86] [87] [88] . Additionally, the authors suggest that these nanoparticles may be recognized by toll-like receptors and, therefore, stimulate the major histocompatibility complex class I, a restricted T-cell response associated with thymocyte migration to the periphery [89] [90] [91] . We hypothesize that based on the described phenomena and our results, FC60-induced activation of the cell-mediated immune response can be one potential cause of a decrease in the thymus weight in mice treated with either FC 60 or the C 60 +Cis complex.
Conclusions
In this work, we present in silico, in vitro, and in vivo studies on the biological activity of the novel nanoformulation of Cis immobilized on the surface of FC 60 . The complexation of Cis with FC 60 increases the cytotoxicity of the drug toward the evaluated tumor cell lines, including Cis-resistant sublines. The obtained results of the cell cycle analysis and DAPI/Annexin V staining attribute to the increased proapoptotic potential of the C 60 +Cis complex. The results of the molecular docking studies reveal that the binding of FC 60 to the three principal plasma membrane transporters involved in the efflux of anticancer drugs, namely P-gp, MRP-1, and MRP-2, may be the mechanism involved in overcoming drug resistance with the C 60 +Cis complex.
Furthermore, in vivo studies with C57BL/6J male mice bearing LLC as a model reveal a corresponding increase in the antitumor activity of Cis complexed with FC 60 . The treatment with the C 60 +Cis complex resulted in a two-fold increase in the inhibition of tumor growth compared to that by Cis and FC 60 alone. Moreover, metastases in mice treated with the C 60 +Cis complex are characterized by the lowest total volume and average size. The observed phenomena may be associated with an abatement of tumor-associated splenomegaly, as well as a decrease in the thymus weight. Additionally, the diminished mutagenic activity of the C 60 +Cis complex, compared to that of Cis alone, may suggest a reduction in the probability of a secondary neoplasm formation induced by Cis.
The results presented in this study support our initial hypothesis of a synergy in the biological activity of FC 60 and Cis, which may be associated with their ability to form non-covalent complexes under physiological conditions. Moreover, our results suggest that a potential tumor treatment with an FC 60 and Cis complex may be a promising approach in the development of new anticancer therapies for pre-and clinical trials.
Methods

Materials preparation
Preparation of C 60 fullerene aqueous colloid solution
The pristine FC 60 aqueous colloid solution (0.15 mg/mL) used in this study was prepared according to previous protocols [92, 93] .
Preparation of the cisplatin complex with C 60 fullerene
Cis solution (Cisplatin-TEVA, Pharmachemie B.V., 0.15 mg/mL) was immobilized on FC 60 according to a protocol developed by our research group [32] . The initial Cis and FC 60 aqueous solution were mixed at a 1:1 volume ratio (FC 60 :Cis molar ratio 1:2.4). Then, the mixture was treated for 20 min in an ultrasonic disperser and left overnight on a magnetic stir plate at room temperature.
Small angle X-ray scattering measurements
SAXS experiments were performed at the P12 BioSAXS Beamline at PETRA III ring (EMBL/DESY) by using Nano Res. 2017, 10(2): 652-671 the 100 (V) μM × 200 (H) μm X-ray beam and energy 10 keV. The sample-to-detector distance (3.1 m) resulted in the q-range of 0.07-4.6 nm -1 after calibration using silver behenate [94] . Scattering patterns were recorded using a Pilatus 2M pixel detector. The samples (20 μL) were injected into the sample capillary by using an automated sample changer. The sample was moved during the exposure to reduce the risk of radiation damage. Twenty consecutive frames (0.05 s) containing the sample and buffer measurements were performed at 20 °C . All scatter curves were compared to the reference measurement (typically the first exposure) to verify there were no artifacts, and then integrated with an automated acquisition program [95] . The pure buffer signal was read pre-and post-sample measurement and used for background subtraction. All of the data were normalized to the transmitted beam and processed using an indirect Fourier transformation approach developed by Glatter [37] and using the GNOM program [96] .
Molecular docking
P-glycoprotein
Protein data banks PDB, PDBe, and pfam contain only murine P-gp structures. Therefore, as this study was conducted on human tumor cell lines, all attainable P-gp structures were compared with each other by using ClustalW software. The most representative structure, 4M1M, was selected [97] and further used as a template for constructing a human P-gp model, which was built on the Swiss-Model online server (www.expasy.ch/swissmod).
Multidrug resistance protein 1
All attainable structures of MRP-1 were analyzed using ClustalW software and the most representative structure, 2CBZ, was selected [98] .
Multidrug resistance protein 2 (MRP-2)
On the basis of the PDB structure of MRP-2 for Plasmodium yoelii (PDB ID: 2GHI (crystalline structure of Plasmodium yoelii multidrug resistance protein 2)) [99] , we conducted a homologous simulation of the MRP-2 structure to the human organism. The amino acid sequence of MRP-2 was obtained from the UniProt ID sequence Q92887. During the sequence comparison, the 2GHI structure showed a lower similarity to the human sequence (identity, 30.6%, similarity, 44.3%) than the 2CBZ structure (identity, 60.6%, similarity, 70.6%; structure used for modeling of the FC 60 +MRP-1 complex). In addition, when the 2CBZ and 2GHI structures were compared, it was revealed that all secondary structures overlapped. Therefore, the 2CBZ structure [98] was used as the template for the homologous modeling of the MRP-2 structure to the human organism.
Molecular docking simulation
Water molecules were removed from the selected proteins and Arg and Lys residues were protonated. The procedure was performed using the flexible ligand model using a systematic docking algorithm (sdock+) [100] . A hundred calculation steps were performed for each protein and the 10 best FC 60 -protein complexes (based on QXP scoring functions [101] ) were further analyzed. The mobility range of all of the interacting structures, from small side chains to large-scale domain movements, was considered throughout the calculations. The following energy types were evaluated: FreE-the energy of the complex; Cntcthe energy of the interactions between FC 60 and the protein; Bump-the energy of steric clashes between FC 60 and protein.
Cytotoxicity studies
Human isogenic p54-null (p53−/−), Bax-null (Bax−/−), and wild-type (p53+/+, Bax+/+) HCT-116 colon carcinoma cell lines were kindly provided by Bert Vogelstein at John Hopkins University (Baltimore, MD, USA). Human cervical cancer cell lines, HeLa and human Jurkat T-leukemia cell lines were purchased from ATCC. The human cervix carcinoma cell line, KB-3-1, and its colchicine-selected KBC-1 subline (P-gp overexpressing) were a generous gift from Dr. Shen at National Institutes of Health (Bethesda, MD, USA). The human leukemia cell line, HL-60, and its drugresistant sublines, HL-60/adr (overexpressing of MRP-1) and HL-60/vinc (P-gp overexpressing), were donated by Dr. M. Center at Kansas State University (Manhattan, KS, USA). Nano Res. 2017, 10(2): 652-671 Cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum 50 μg/mL streptomycin, and 50 units/mL penicillin (all materials were from Sigma-Aldrich, St. Louis, MO, USA) in a 5% CO 2 humidified atmosphere at 37 °C . During experiments, cells were incubated for 24 h in 24-well tissue culture plates (Greiner Bio-one, Frickenhausen, Germany). The cytotoxic effects of Cis and the C 60 +Cis complex were evaluated by staining the dead cells with Trypan blue (0.1%) and visualized using an Evolution 300 Trino optical microscope (Delta Optical, Nowe Osiny, Poland).
Chromatin condensation study
Human cervix carcinoma, KB-3-1, treated with FC 60 , Cis, and the C 60 +Cis complex were stained with 4',6-diamidino-2-phenylindole (DAPI, Sigma Aldrich, St. Louis, MO, USA) as a nuclear chromatin condensation analysis. After 24 h incubation with the analyzed chemicals, cells were washed twice with PBS, fixed in paraformaldehyde (4% solution) for 15 min at room temperature, and permeabilized with 0.1% Triton X-100 in PBS for 3 min. Subsequently, cells were incubated with 1 μg/mL DAPI solution for 5 min, washed twice with PBS, and, finally, put on cover glasses and placed on slides. A cytomorphological study was performed using a Carl Zeiss AxioImager A1 fluorescent microscope (Carl Zeiss, Gottingen, Germany).
Apoptosis analysis
Apoptosis was assessed by staining cells with Annexin-V-FITC and PI by using an apoptosis detection kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions 24 h after the addition of the analyzed chemicals to the cells. Subsequently, the cells were centrifuged at 600g, washed with PBS twice, and incubated for 15 min in the Annexin V binding buffer containing 1/50 volume of FITC conjugated Annexin V solution and PI. Next, Annexin V binding buffer was added to dilute samples twice and the samples were measured using an FACScan flow cytometer (Becton Dickinson, East Rutherford, NJ, USA). A cell cycle analysis was conducted using Cytomation Summit Software v3.1 (Cytomation Inc., Fort Collins, CO, USA). Different cell lines used in the procedures mentioned in sections 4.5 and 4.6 are the results of different properties required for each of the analyses. The KB-3-1 cell line is an adherent cell line, which should undergo trypsinization. Consequently, trypsinization may affect the cell membranes integrity, producing false positive results. In contrast, the HL-60/adr leukemia cell line is grown in suspension and, thus, cannot be properly stained with DAPI.
Cell cycle analysis
The cell cycle of the analyzed cells was assessed according to the protocol described by Walker et al. [102] . After a 24-h incubation with the analyzed chemicals, 2 × 10 6 cells were collected and pelleted by centrifugation at 250g for 5 min at 4 °C . Subsequently, the cells were resuspended in 1 mL of cold PBS and fixed using 4 mL of ethanol (at −20 °C ) dropwise. On the next day, the fixed cells were centrifuged again and the pellet was resuspended in 1 mL of PBS. Then, the cell suspension was incubated for 30 min at 37 °C with 100 μL of 200 μg/mL RNase A (Invitrogen, Carlsbad, CA, USA). Next, the samples were incubated for 10 min at room temperature with 100 μL of 1 mg/mL PI solution. After staining, the samples were analyzed using a FACScan flow cytometer.
Ames mutagenicity test
The Salmonella typhimurium TA102 strain used in the Ames mutagenicity test was kindly provided by Prof. H. Czeczot from the Department of Biochemistry at the Medical University of Warsaw (Poland). Ampicillin, histidine, and biotin were purchased from Sigma Aldrich. The Salmonella mutagenicity test was performed without metabolic activation according to the procedure described by Mortelmans and Zeiger [103] with modifications introduced by Woziwodzka et al. [68] .
A mixture containing 100 μL of an overnight culture of S. typhimurium TA102 (corresponding to 1 × 10 8 colony forming units), 50 μL of 3% NaCl, and 100 μL of test chemicals dilution (or sterile water for the negative control) was incubated for 4 h in the dark at 37 °C and 220 rpm. Then, the mixture was centrifuged, and the bacterial pellet was washed with 0.75% NaCl and re-suspended in 300 μL of 0.75% NaCl solution Nano Res. 2017, 10(2): 652-671 containing 0.1 μmol histidine and 0.1 μmol biotin. Finally, it was spread on a glucose minimal (GM) plate. All experiments were performed in triplicate. After a 48-h incubation at 37 °C in the dark, the number of revertant colonies was calculated. Possible bacterial toxicity was determined by the observation of the auxotrophic background (background lawn). The analyzed FC 60 concentration was proven non-toxic toward S. typhimurium TA102, as no alterations in the background lawn were observed.
In vivo procedures
The male mice (18-19 g ) from the C57BL/6J line were bred and maintained on a standard diet at 25 ± 1 °C in the animal facility of R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine (Kyiv, Ukraine). All experiments were conducted in accordance with the international regulations of the European Convention for protection of vertebrate animals under control of the Bio-Ethical Committee of the NAS of Ukraine.
The National Bank of Cell Lines and Transplanted Tumors at R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine kindly provided the LLC cells. The mice were randomized by weight and divided into 5 groups (10 animals per group). Four of them received a transplantation of 3 × 10 5 tumor cells into the limb, via intramuscular injection. These groups were intraperitoneally injected with: (1) saline (control group), (2) FC 60 at a dose of 0.5 mg per kg of body mass (group 1), (3) Cis at a dose of 1.25 mg per kg of body mass (group 2), and (4) the C 60 +Cis complex at a dose of 1.25 mg per kg of body mass (group 3). The remaining, fifth group of mice did not undergo tumor transplantation (intact animals). The analyzed substances were injected every other day for a total period of 10 days, with the first injection on the second day after tumor transplantation. The protocol of FC60 administration and the applied dose were established on the basis of a previously described protocol [17] .
The kinetics of LLC tumor growth in mice was characterized by the observation of a change in tumor size from day 11 (visual observation, increase in tumor volume) to day 20. On day 22 (first death in the control group), mice from all groups were killed by cervical dislocation and autopsied to calculate the number of lung metastases. Every mouse from each group and their organs (namely the thymus, liver, and spleen) were weighed.
The antitumor efficacy of the proposed treatment was estimated by the following indicators [19, 22] tumor volume (V, mm 3 )
where a and b are the long and short diameters of the tumor (mm), respectively; tumor growth inhibition index (TGII, %)
where V C and V Exp are the average tumor volumes in animals in the control and experimental groups, respectively; metastasis volume (VM, mm 3 )
where d is the linear size of the metastatic nodule (mm); thymus and spleen indices
where m O and m are the weight of the animal's organs (g) and body (g), respectively.
Statistical analysis
All ex vivo experiments were performed in triplicate. The results were evaluated using the Student's t-test. The results of the Ames test were evaluated using Statistica 9.1 (StatSoft) software. A one-way analysis of variance was applied followed by the post-hoc Tukey's HSD test. The significance level was established at α = 0.05. 
